Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Single Arm, Observational Phase IV Study to Assess the Safety and Efficacy of Nelarabine in Children and Young Adults (up to 21 Years of Age) With Relapsed or Refractory T-Lineage Acute Lymphoblastic Leukaemia or Lymphoblastic Lymphoma

NCT00866671 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00866671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00866671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Single Arm, Observational Phase IV Study to Assess the Safety and Efficacy of Nelarabine in Children and Young Adults (up to 21 Years of Age) With Relapsed or Refractory T-Lineage Acute Lymphoblastic Leukaemia or Lymphoblastic Lymphoma
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
February 28, 2009
Completion date
September 30, 2014
Enrollment
28 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

leukaemia, lymphoblastic, acute